Unicorn Capital Partners, a biotech-specialized VC fund, and AstraZeneca Pharmaceuticals have entered into an investment agreement with Target Medicals. While the financing size is not disclosed, the funding will support the completion of preclinical proof-of-concept studies, aiming to nominate a drug candidate for further clinical trials.